Ardelyx’s constipation drug succeeds in late-stage trial

Share this post

(Reuters) – Ardelyx Inc said on Wednesday a second late-stage trial of its experimental drug for irritable bowel syndrome with constipation (IBS-C) met the main goal of reducing abdominal pain and increasing bowel movement.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply